Evaxion’s Advanced AI-Immunology Platform Excels Across Various Clinical Trials
Evaxion Biotech, a techbio firm based in Denmark, has revealed findings from three clinical trials that compare its AI-Immunology platform’s prediction scores with the immunological responses observed in patients.
This advanced AI-immunology platform specializes in pinpointing neoantigens—specific targets crucial for developing cancer vaccines—while also forecasting the immune response a patient might have to these vaccine targets against tumors. The analysis of data from the three trials demonstrated that the vaccine targets identified with the highest scores from the AI predictions corresponded to more robust immunological responses in patients, indicating the effectiveness of the platform in selecting impactful cancer vaccine targets.
Evaxion’s AI-Immunology platform consists of several proprietary AI models designed to simulate the human immune system. This comprehensive system is capable of identifying, predicting, and creating vaccine candidates for both infectious diseases and cancers. To date, the platform has aided in the creation of three personalized cancer vaccines: two have completed Phase I trials, while one is currently in the IND stage. The company’s candidates targeting infectious diseases are in the early stages of development.
Leading the portfolio is EVX-01, a personalized peptide-based cancer vaccine designed to treat metastatic melanoma as a first-line treatment, developed using this innovative AI-Immunology platform. In a small Phase 1/2a trial, EVX-01 showed significant promise, with 67% of patients benefiting from its use in combination with Merck’s PD-1 inhibitor, Keytruda, compared to only 33-40% of patients experiencing benefits from the PD-1 inhibitor alone, according to historical comparisons.
The safety and efficacy of the EVX-01 and Keytruda combination therapy are currently under investigation in a Phase 2 clinical trial spanning clinical sites across the United States, Europe, and Australia.
The second candidate, EVX-02, is designed as a DNA-based cancer immunotherapy intended to elicit a therapeutic immune response in patients with Stage III and IV melanoma who have undergone first-line treatment.
EVX-03 focuses on advanced solid tumors and is also a DNA-based immunotherapy.
In light of the encouraging results from the clinical trials, Christian Kanstrup, CEO of Evaxion, commented: “We take pride in demonstrating such compelling clinical data that highlights the unique predictive strengths of the AI-Immunology™ platform across multiple clinical trials. The evident correlation between the prediction scores and clinical outcomes provides us with valuable insights for advancing the personalized cancer vaccines based on AI-Immunology™. This generation of significant clinical data is crucial for maintaining our iterative learning approach, which supports the ongoing enhancement of AI-Immunology™.”